Enlitic, Inc. (ASX: ENL) has reached an agreement to sell CXR Focal Opacity, Enlitic’s chest x-ray technology, to Clairvo Technologies for a cash consideration of US$500,000.
CXR Focal Opacity is a detection and triage technology which aids the detection of abnormalities in chest x-rays. As Enlitic’s growth strategy has evolved to focus on its core competencies in data standardisation, this technology has become non-core. Clairvo have previously distributed CXR Focal Opacity in Japan and remains a distributor of Enlitic’s core products in Japan.
Under the terms of the agreement, Enlitic assigns its right, title and interest in CXR Focal Opacity to Clairvo and also grants Clairvo perpetual non-exclusive licenses of certain patents relevant to CXR Focal Opacity and to certain Enlitic Background IP as needed by Clairvo to use and practice CXR Focal Opacity.
Clairvo is a wholly owned subsidiary of Marubeni Corporation, which holds approximately 12.3% of the shares in Enlitic at the date of this announcement.
